Abstract
Background
When psoriasis affects scalp, nails, palms and soles, it is considered difficult to treat and causes severe impairment of life quality.
Objective
We evaluated which difficult site most impacts on the patient’s quality of life and how quality of life changes during treatment.
Methods
We conducted a prospective observational study in patients receiving adalimumab over a 24 weeks period, through assessment at weeks 0, 4 and 24 using PASI, PAIN VAS, ITCH VAS, DLQI, NAPSI, PSSI. Pearson correlation was used to evaluate the relationship between the various measurements on the basis of three different deltas (between T0 and T24, between T0 and T4, between T0 and average between T4 and T24)
Results
The correlation matrix between T0 and T24 shows a significant correlation between delta PASI and delta ITCH and delta ITCH and delta DLQI and a significant correlation between ITCH delta and DLQI delta and a correlation close to significance between DLQI and NAPSI.
Conclusion
We identified itching as a mediator between the cutaneous extension of psoriasis and the impact on quality of life. We also documented the predominant role of nail psoriasis in defining the impact on the quality of life of the psoriatic patient.
Acknowledgements
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. We thank Dr. Giorgia De Angelis for English editing.
Ethics approval
Ethic committee approved the study.
Consent to participate
Every patient signed an informed consent to participate to the study according to Helsinki declaration.
Consent for publication
Every patient signed an informed consent for eventual publication.
Disclosure statement
No potential conflict of interest was reported by the author(s).